The U.S. Food and Drug Administration (FDA) has approved Zolinza or vorinostat (manufactured by Pantheon for Merck) for treating relapse or worsening cutaneous T-cell lymphoma (CTCL), a type of skin cancer. This is a rare type of skin cancer that affects about 3 in every 1 million people in the US, usually men over age 50. (More …)